Off the Scales
The Inside Story of Ozempic and the Race to Cure Obesity
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
2か月無料体験
聴き放題対象外タイトルです。プレミアム会員登録で、非会員価格の30％OFFで予約注文できます。
聴けるのは配信日からとなります。
Off the Scales
￥2,600で今すぐ予約注文する
-
ナレーター：
-
Yael Rizowy
-
著者：
-
Aimee Donnellan
このコンテンツについて
The inside story of the creation of Ozempic and its revolutionary impact on public health.
A “cure” for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates a hormone in the stomach called GLP-1, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industries—from healthcare to fast food to fashion—and it has quickly made its creator, Denmark’s Novo Nordisk, the most valuable company in Europe. But the impact of GLP-1s goes far beyond billion-dollar profits; a true long-term cure for obesity could save 40 percent of American adults from dangerous, preventable illnesses. And as more potential benefits emerge, one question looms in the minds of investors, healthcare workers, and politicians: Are these drugs too good to be true?
In Off the Scales, Reuters journalist Aimee Donnellan illuminates the history of a medical breakthrough that is poised to change the world, while raising difficult social questions about inequality and morality. Through original reporting and rigorous research, she forecasts the future of GLP-1s and examines what their explosive popularity tells us about our ideals of beauty and the lengths to which people will go in order to become thin.
Along the way, Donnellan profiles the scientist whose contributions to the discovery of GLP-1 were overlooked, documents her fight for recognition while her colleagues were thrust into the limelight, and offers new insights into the ways that the food and beauty industries made billions while promoting unhealthy and unrealistic body image standards and accelerating the obesity crisis. She also provides firsthand accounts of several early Ozempic users and the transformative effect the drug has had on their weight loss journeys.
Off the Scales is an informative and entertaining study of the unexpected consequences of finally getting what we’ve wanted for so long.
©2025 Aimee Donnellan (P)2025 Macmillan Audio批評家のレビュー
"Ozempic and the other GLP-1 medications are among the most important medical breakthroughs of our time. Off the Scales captures the many facets of this fast-moving story, including the decades of scientific research that led to their creation, the stories of early patients and the culture change required to understand obesity as a medical condition rather than a character flaw. Donnellan is a gifted storyteller who brings complicated subjects to life and offers a hopeful vision for how these therapies are transforming lives and reshaping our approach to health care."—Leana Wen, M.D., Washington Post contributing columnist and author of Lifelines
“The creation of Ozempic has changed lives and challenged long-held assumptions about obesity, but it also raises a whole set of new questions. Donnellan chronicles the search for miracles, the ensuing gold rush, the lives impacted, the biases overturned and solidified, and where this paradigm shift will leave us. Off the Scales is the definitive account of a singular global force—essential reading to help us understand what has been unleashed and what may be coming next."—Andy Slavitt, author of Preventable
"Off the Scales is the fascinating and thoroughly researched story of a medical miracle. Aimee Donnellan has tackled a complex subject—the discovery of GLP-1s—and distilled it into an engaging and deeply compassionate study of a breakthrough that is poised to change society, for better or worse (or maybe both). An essential read for our times."—Jonathan Cohn, author of The Ten Year War and Sick